Stribild PEP Substudy

PreclinicalSmall molecule

UUniversity of California, San Francisco

Stribild PEP Substudy is one of 4 small molecule programs targeting NEC. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NECCompleted

NECPreclinical

Completed

Competition

Competitive Landscape

3 competitors in NEC

#DrugCompanyPhaseTrials

Zepzelca

Jazz Pharmaceuticals

Phase 2

1 2

Cosela

PPharmacosmos A/S

Phase 2

1 3

Stribild PEP Substudy

UUniversity of California, San Francisco

Preclinical

1 4

Painkillers

UUniversity of Valencia

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

NEC1 trial

Connecting Resources for Urban Sexual Health

Completed·UUniversity of California, San Francisco·N/A·NCT02183909·378 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Stribild PEP Substudy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Stribild PEP Substudy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Stribild PEP Substudy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Francisco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of California, San Francisco

Stribild PEP Substudy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

NEC1 trial

References

Drug Info

Quick Facts

Related News